JAMA Internal Medicine
JUNE 30, 2024
This randomized clinical trial assesses whether sensorimotor training and whole-body vibration training reduce symptoms and decrease the onset of chemotherapy-induced peripheral neuropathy.
pharmaphorum
JUNE 30, 2024
After FDA rejection last year, ARS Pharma closes on EU approval for intranasal epinephrine product for anaphylaxis
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
JAMA Internal Medicine
JUNE 30, 2024
This cohort study examines the use of routine electrocardiogram (ECG) screening in identifying individuals at risk for cardiovascular disease.
Drug Patent Watch
JUNE 30, 2024
This chart shows the pharmaceutical companies with the most patents in Lithuania. Patents must be filed in each country (or, in some cases regional patent office) where patent protection is desired.
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
Cloudbyz
JUNE 30, 2024
The Accelerated Approval Program of the FDA provides for conditional approval of drugs that show an effect sufficiently desirable, compared to available medications, based on surrogate endpoints considered reasonably likely to predict clinical benefit. This path acknowledges the urgency that some medical conditions carry and tries to provide earlier access to potentially life-saving therapies for patients.
Drug Patent Watch
JUNE 30, 2024
Dabigatran etexilate mesylate is the generic ingredient in two branded drugs marketed by Alkem Labs Ltd, Apotex, Hetero Labs Ltd Iii, and Boehringer Ingelheim and, and is included in five NDAs.
FDA Law Blog
JUNE 30, 2024
RAPS Convergence 2024 is set to host a must-attend session on CDRH’s Total Product Life Cycle Advisory Program (TAP), promising attendees an exclusive insight into a pioneering initiative aimed at improving the medical device commercialization landscape. Session Details: A Path to Faster Breakthrough Device Commercialization – CDRH’s Total Product Life Cycle Advisory Program (TAP) Thursday, September 19, 2024, 4:30 PM – 5:30 PM Session Leader: Adrienne Lenz, RAC – Principal Medical Device Regula
Expert insights. Personalized for you.
108 
Let's personalize your content